Use of erythropoietin for the preventive or curative treatment of cardiac failure

• US 7,335,490 B2
• Filed: 01/09/2003
• Issued: 02/26/2008
• Est. Priority Date: 01/09/2002
• Status: Expired due to Fees

• Current Assignee: Crucell Holland B.V (Johnson & Johnson), Stichting Klinische Farmacologie Groningen
• Original Assignee: Crucell Holland B.V (Johnson & Johnson), Stichting Klinische Farmacologie Groningen
• Inventors: Van Veldhuisen, Dirk Jan, Henning, Robert Henk, De Boer, Rudolf Allert, Brus, Ronald Hendrik Peter, Van Gilst, Wiekert Hendrikus
• Primary Examiner(s): Mondesi; Robert B.
• Application Number:
  US10/500,913
• Publication Number:
  US 20050075287A1
• Time in Patent Office: 1,874 Days
• Field of Search: 530/350, 514/12, 435/69.1, 435/7.1
• US Class Current: 435/69.1
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Provided are uses of erythropoietin, or a derivative or functional analogue thereof, for the production of a medicament for the preventive or curative treatment of patients suffering from, or at risk of suffering from, cardiac failure.

Claims

1. A method of treating a patient suffering from chronic heart failure, the method comprising:

producing erythropoietin (EPO) in an isolated host cell expressing at least the Early Region 1A (E1A) protein of an adenovirus, wherein said host cell is a cell as deposited under European Collection of Animal Cell Cultures (ECACC) no. 96022940;

preparing a medicament comprising said EPO for the treatment of a patient suffering from chronic heart failure; and

administering said medicament to said patient.

2. The method according to claim 1, wherein said patient is non-anemic.

3. The method according to claim 1, wherein the subject is non-anemic.

4. A method of treating a subject suffering from chronic heart failure, the method comprising:

administering to the subject erythropoietin (EPO), wherein the EPO has been produced by a process comprising;

expressing EPO in an isolated host cell that expresses Early Region 1A (E1A) protein of an adenovirus, wherein said host cell is a cell as deposited under European Collection of Animal Cell Cultures (ECACC) no. 96022940.